(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Alpha-1 Antitrypsin Deficiency
Arrowhead PharmaceuticalsSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Alpha-1 Antitrypsin Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Wve-006 Wave Life Sciences USA, Inc. | Phase 1/2 | B |
Kamada-Aat For Inhalation Kamada, Ltd. | Phase 2 | B |
Arc-Aat Arrowhead Pharmaceuticals | Phase 2 | B |
Acetylsalicylic Acid Columbia University | Phase 2 | B |
vx-864 Vertex Pharmaceuticals Incorporated | Phase 2 | CCC |
View all 17 →
Same molecule, other indications
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →